Scott R Nodzo1, Keely K Boyle2, Sonja Pavlesen3, Sridhar Rachala3. 1. Department of Orthopaedics, University at Buffalo Department of Orthopaedics, 462 Grider Street, Buffalo, NY, 14215, USA. Spodzo@gmail.com. 2. Department of Orthopaedics, University at Buffalo Department of Orthopaedics, 462 Grider Street, Buffalo, NY, 14215, USA. 3. University at Buffalo Department of Orthopaedics, 100 High Street, Buffalo, NY, 14203, USA.
Abstract
INTRODUCTION: The restoration of acetabular bone stock during revision hip arthroplasty remains a challenge. There have been no clinical series reporting the efficacy of bone morphogenic protein-2 (rhBMP-2) in the revision hip setting. METHODS: We retrospectively reviewed the radiographs and records of 15 patients who received rhBMP-2 mixed with allograft bone chips (+BMP), and 14 who received allograft bone chips alone (-BMP) for their acetabular defect during revision total hip arthroplasty with a mean two-year follow up. Radiographs were evaluated for acetabular defect size, superior cup migration, and changes in the lateral cup abduction angle. Modified Harris hip scores were used for evaluation of clinical outcomes. RESULTS: Patients in the +BMP group compared to the -BMP group had significantly larger amounts of cancellous bone chips used (72.1 ± 35.5 cc vs. 38.6 ± 14.1 cc; p = 0.003). Mean rhBMP-2 used per case was 7.4 ± 3.1 mg in the +BMP group. Three patients in the -BMP group had cup migration which was not observed in the +BMP group. Mean Harris hip scores (HHS) improved post-operatively in both groups (40.1 ± 20.9 to 71.9 ± 19, p < .0001). No local adverse reaction was noted in the +BMP group. CONCLUSION: rhBMP-2 had modest clinical benefit in the setting of revision THA. Cost of this synthetic biologic versus the added clinical benefit should be carefully considered when being used in the revision hip setting.
INTRODUCTION: The restoration of acetabular bone stock during revision hip arthroplasty remains a challenge. There have been no clinical series reporting the efficacy of bone morphogenic protein-2 (rhBMP-2) in the revision hip setting. METHODS: We retrospectively reviewed the radiographs and records of 15 patients who received rhBMP-2 mixed with allograft bone chips (+BMP), and 14 who received allograft bone chips alone (-BMP) for their acetabular defect during revision total hip arthroplasty with a mean two-year follow up. Radiographs were evaluated for acetabular defect size, superior cup migration, and changes in the lateral cup abduction angle. Modified Harris hip scores were used for evaluation of clinical outcomes. RESULTS:Patients in the +BMP group compared to the -BMP group had significantly larger amounts of cancellous bone chips used (72.1 ± 35.5 cc vs. 38.6 ± 14.1 cc; p = 0.003). Mean rhBMP-2 used per case was 7.4 ± 3.1 mg in the +BMP group. Three patients in the -BMP group had cup migration which was not observed in the +BMP group. Mean Harris hip scores (HHS) improved post-operatively in both groups (40.1 ± 20.9 to 71.9 ± 19, p < .0001). No local adverse reaction was noted in the +BMP group. CONCLUSION: rhBMP-2 had modest clinical benefit in the setting of revision THA. Cost of this synthetic biologic versus the added clinical benefit should be carefully considered when being used in the revision hip setting.
Entities:
Keywords:
Acetabular defects; Arthroplasty; Bone graft; Bone morphogenic protein; Revision total hip
Authors: Hongwei Cheng; Wei Jiang; Frank M Phillips; Rex C Haydon; Ying Peng; Lan Zhou; Hue H Luu; Naili An; Benjamin Breyer; Pantila Vanichakarn; Jan Paul Szatkowski; Jae Yoon Park; Tong-Chuan He Journal: J Bone Joint Surg Am Date: 2003-08 Impact factor: 5.284
Authors: Margaret A McGee; David M Findlay; Donald W Howie; Angelo Carbone; Peter Ward; Roumen Stamenkov; Tara T Page; Warrick J Bruce; Corinna I Wildenauer; Carol Toth Journal: J Orthop Res Date: 2004-09 Impact factor: 3.494
Authors: Jonathan P Van Kleunen; Gwo-Chin Lee; Peter W Lementowski; Charles L Nelson; Jonathan P Garino Journal: J Arthroplasty Date: 2009-04-01 Impact factor: 4.757
Authors: Rozalia Dimitriou; George I Mataliotakis; Antonios G Angoules; Nikolaos K Kanakaris; Peter V Giannoudis Journal: Injury Date: 2011-06-25 Impact factor: 2.586
Authors: Alexander Wurm; Dietmar Dammerer; Michael Christian Liebensteiner; Michael Nogler; Christoph Ammann; DÉbora CoraÇa-Huber Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155